Skip to main content
Equibles
OSRH logo

OSRH · OSR Health, Inc.

Track OSRH — free

Use OSRH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OSRH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.17 +0.05 (+43.78%) At close · Aug 26
Rebalance outlook locked
Customer concentration — top 3 customers 95% of revenue

3 customers — 95% of revenue

“Three main customers of RMC have in recent years represented approximately 95% of RMC's total sales.”
View the 10-K filed Mar 31, 2026
Market Cap
$4.09M
Shares
35.12M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.17 Open$0.09 Day$0.08–0.19 52W close$0.12–0.98 Avg vol 30d20.2M Short int1.2M · 3.5% float · 1.4d Short vol38% DataMar 2023–Aug 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.81M
Trailing 12 months
Net income (TTM)
−$14.91M
Trailing 12 months
Revenue growth YoY
-72.2%
Year over year
Operating margin
-933.7%
Trailing 12 months
P / E (TTM)
538.0
Trailing earnings · reciprocal yield 0.2%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$955,553
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+214.2%
Year over year · more shares
Price change (1Y)
-82.9%
Trailing year
Short interest
—
Latest settlement
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −67%
below
Price vs 50-day avg −55%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 6%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −65%
trailing
6-month return −64%
trailing
YTD return −70%
this year
Relative strength −77%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.48% of float · ▲ +16.5% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — mid 3-yr range
Fundamentals
Fair
Revenue growth −18%
Y/Y
Gross margin 20%
contracting
EPS growth +83%
Y/Y
Quant / Vol
risk profile
Very High
Volatility 177%
annualized · 1-yr
Max drawdown −88%
past year
ATR 63.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−67% Bearish
Price vs 50-day avg
−55% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
6% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.48% of float · ▲ +16.5% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 6% Range high $1
vs 200-day avg -67% vs 50-day avg -55%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OSRH
OSR Health, Inc.
this stock
$4.09M -70.3% -17.7% — 3.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
29
% held
11.5%
Net QoQ
-162.1K sh
Top holder
TORONTO DOMINION BANK
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
1.4d
Change
+173.3K sh
View
Short Volume
Short vol %
38%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
533
Value
$229
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
63.1%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.9M
Net income (FY)
$-2.4M
EPS diluted
$-0.80
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 28, 2026
This year
24
View

Performance

5D 20D 120D MTD YTD
OSRH -55.1% -64.7% -64.3% -62.6% -70.3%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY -54.7% -69.7% -76.7% -65.2% -82.6%
Key facts CIK 1840425 CUSIP 68840D102 13F (30d) 10 filings 10 filers Visit website Investor relations